

Markus M Forsberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2555339/publications.pdf>

Version: 2024-02-01

52
papers

1,606
citations

304743

22
h-index

302126

39
g-index

53
all docs

53
docs citations

53
times ranked

2280
citing authors

#	ARTICLE	IF	CITATIONS
1	A smart hospital-driven approach to precision pharmacovigilance. Trends in Pharmacological Sciences, 2022, 43, 473-481.	8.7	5
2	Phencyclidine-induced cognitive impairments in repeated touchscreen visual reversal learning tests in rats. Behavioural Brain Research, 2021, 404, 113057.	2.2	4
3	Species differences in the intra-brain distribution of an L-type amino acid transporter 1 (LAT1) -utilizing compound between mice and rats. International Journal of Pharmaceutics, 2021, 596, 120300.	5.2	5
4	Alcohol Co-Administration Changes Mephedrone-Induced Alterations of Neuronal Activity. Frontiers in Pharmacology, 2021, 12, 679759.	3.5	1
5	Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats. Psychopharmacology, 2019, 236, 1245-1253.	3.1	11
6	Sleep-State Dependent Alterations in Brain Functional Connectivity under Urethane Anesthesia in a Rat Model of Early-Stage Parkinson's Disease. ENeuro, 2019, 6, ENEURO.0456-18.2019.	1.9	9
7	Discovery of polar spirocyclic orally bioavailable urea inhibitors of soluble epoxide hydrolase. Bioorganic Chemistry, 2018, 80, 655-667.	4.1	21
8	Combined ipsilateral limb use score as an index of motor deficits and neurorestoration in parkinsonian rats. Journal of Neuroscience Research, 2017, 95, 1858-1870.	2.9	9
9	Brief isoflurane anesthesia regulates striatal AKT/SGSK3 signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease. Journal of Neurochemistry, 2017, 142, 456-463.	3.9	22
10	Dose-response effect of acute phencyclidine on functional connectivity and dopamine levels, and their association with schizophrenia-like symptom classes in rat. Neuropharmacology, 2017, 119, 15-25.	4.1	13
11	Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease. Pharmaceutical Research, 2017, 34, 2652-2662.	3.5	11
12	Genetically Modified Caco-2 Cells With Improved Cytochrome P450 Metabolic Capacity. Journal of Pharmaceutical Sciences, 2016, 105, 941-949.	3.3	25
13	Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835. Bioorganic and Medicinal Chemistry, 2016, 24, 5481-5494.	3.0	22
14	Comparison of phencyclidine-induced spatial learning and memory deficits and reversal by sertindole and risperidone between Lister Hooded and Wistar rats. Behavioural Brain Research, 2016, 305, 140-147.	2.2	9
15	Comparison of seven different anesthesia protocols for nicotine pharmacologic magnetic resonance imaging in rat. European Neuropsychopharmacology, 2016, 26, 518-531.	0.7	52
16	Brain Pharmacokinetics of Ganciclovir in Rats with Orthotopic BT4C Glioma. Drug Metabolism and Disposition, 2015, 43, 140-146.	3.3	14
17	Re-evaluation of the role of P-glycoprotein in vitro drug permeability studies with the bovine brain microvessel endothelial cells. Xenobiotica, 2014, 44, 283-294.	1.1	4
18	<sc>KYP</sc> 2047 Penetrates Mouse Brain and Effectively Inhibits Mouse Prolyl Oligopeptidase. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 460-463.	2.5	15

#	ARTICLE	IF	CITATIONS
19	Prolyl oligopeptidase inhibition decreases extracellular acetylcholine levels in rat hippocampus and prefrontal cortex. <i>Neuroscience Letters</i> , 2014, 579, 110-113.	2.1	6
20	Design, Synthesis and Brain Uptake of LAT1-Targeted Amino Acid Prodrugs of Dopamine. <i>Pharmaceutical Research</i> , 2013, 30, 2523-2537.	3.5	102
21	Unpredictable Rotational Responses to L-Dopa in the Rat Model of Parkinson's Disease: the Role of L-Dopa Pharmacokinetics and Striatal Dopamine Depletion. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 162-170.	2.5	6
22	Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells. <i>International Journal of Pharmaceutics</i> , 2012, 436, 426-443.	5.2	12
23	The effect of prolyl oligopeptidase inhibition on extracellular acetylcholine and dopamine levels in the rat striatum. <i>Neurochemistry International</i> , 2012, 60, 301-309.	3.8	26
24	Inhibition of prolyl oligopeptidase by KYP-2047 fails to increase the extracellular neurotensin and substance P levels in rat striatum. <i>Neuroscience Letters</i> , 2011, 502, 107-111.	2.1	19
25	Brain Pharmacokinetics of Two Prolyl Oligopeptidase Inhibitors, JTP-4819 and KYP-2047, in the Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 443-451.	2.5	28
26	Prolyl Endopeptidase Is Involved in Cellular Signalling in Human Neuroblastoma SH-SY5Y Cells. <i>NeuroSignals</i> , 2011, 19, 97-109.	0.9	25
27	Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1489-1498.	2.4	4
28	Brain uptake of ketoprofen-L-lysine prodrug in rats. <i>International Journal of Pharmaceutics</i> , 2010, 399, 121-128.	5.2	67
29	Comparison of in vitro cell models in predicting in vivo brain entry of drugs. <i>International Journal of Pharmaceutics</i> , 2010, 402, 27-36.	5.2	55
30	Increase in Free Choice Oral Ethanol Self-Administration in Catechol-O-Methyltransferase Gene-Disrupted Male Mice. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 297-304.	2.5	18
31	Site-Specific Role of Catechol-O-Methyltransferase in Dopamine Overflow within Prefrontal Cortex and Dorsal Striatum. <i>Journal of Neuroscience</i> , 2007, 27, 10196-10209.	3.6	244
32	2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2024-2031.	3.0	17
33	Comparison of the Effects of Deramciclane, Ritanserin and Buspirone on Extracellular Dopamine and Its Metabolites in Striatum and Nucleus Accumbens of Freely Moving Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 102, 071027162142001-???	2.5	9
34	An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5590-5593.	2.2	9
35	Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. <i>Biochemical Pharmacology</i> , 2006, 71, 683-692.	4.4	56
36	The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 24, 503-511.	4.0	21

#	ARTICLE	IF	CITATIONS
37	Dicarboxylic Acid Azacycle-Prolyl-pyrrolidine Amides as Prolyl Oligopeptidase Inhibitors and Three-Dimensional Quantitative Structure-Activity Relationship of the Enzyme-Inhibitor Interactions. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4772-4782.	6.4	14
38	Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 370, 279-289.	3.0	11
39	A Cyclopent-2-enecarbonyl Group Mimics Proline at the P2 Position of Prolyl Oligopeptidase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5605-5607.	6.4	62
40	Absorption rate limit considerations for oral phosphate prodrugs. <i>Pharmaceutical Research</i> , 2003, 20, 848-856.	3.5	72
41	Conformationally rigid N-acyl-5-alkyl-l-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 3611-3619.	3.0	23
42	New Prolyl Oligopeptidase Inhibitors Developed from Dicarboxylic Acid Bis(l-prolyl-pyrrolidine) Amides. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4543-4551.	6.4	17
43	Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 498-506.	2.5	50
44	Dicarboxylic Acidbis(l-Prolyl-pyrrolidine) Amides as Prolyl Oligopeptidase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4581-4584.	6.4	36
45	Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. <i>Biochemical Pharmacology</i> , 2002, 64, 463-471.	4.4	51
46	Pharmacodynamic Response of Entacapone in Rats after Administration of Entacapone Formulations and Prodrugs with Varying Bioavailabilities. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 90, 327-332.	0.0	3
47	Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. <i>European Journal of Neuroscience</i> , 2002, 15, 246-256.	2.6	166
48	4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-l-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 2199-2206.	3.0	36
49	Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats. <i>Journal of Neuroscience Methods</i> , 2001, 109, 47-52.	2.5	9
50	Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatography-tandem mass spectrometry. <i>Biomedical Applications</i> , 2001, 759, 227-236.	1.7	26
51	Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone. <i>Drug Development Research</i> , 2000, 49, 238-244.	2.9	22
52	Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone. <i>Life Sciences</i> , 2000, 67, 205-216.	4.3	29